Identification of Phosphoproteins as Possible Differentiation Markers in All-Trans-Retinoic Acid-Treated Neuroblastoma Cells

Giorgia Mandili¹, Cristina Marini¹, Franco Carta², Cristina Zanini¹, Mauro Prato¹, Amina Khadjavi¹, Franco Turrini¹*, Giuliana Giribaldi¹* *

¹ Dipartimento di Genetica, Biologia e Biochimica, Università di Torino, Torino, Italy, ² Nurex S.R.L., Sassari, Italy

Abstract

Background: Neuroblastic tumors account for 9–10% of pediatric tumors and neuroblastoma (NB) is the first cause of death in pre-school age children. NB is classified in four stages, depending on the extent of spreading. A fifth type of NB, so-called stage 4S (S for special), includes patients with metastatic tumors but with an overall survival that approximates 75% at five years. In most of these cases, the tumor regresses spontaneously and regression is probably associated with delayed neuroblast cell differentiation.

Methodology/Principal Findings: In order to identify new early markers to follow and predict this process for diagnostic and therapeutics intents, we mimicked the differentiation process treating NB cell line SJ-NK-P with all-trans-retinoic acid (ATRA) at different times; therefore the cell proteomic pattern by mass spectrometry and the phosphoproteomic pattern by a 2-DE approach coupled with anti-phosphoserine and anti-phosphotyrosine western blotting were studied.

Conclusions/Significance: Proteomic analysis identified only two proteins whose expression was significantly different in treated cells versus control cells: nucleoside diphosphate kinase A (NDKA) and reticulocalbin-1 (RCN1), which were both downregulated after 9 days of ATRA treatment. However, phosphoproteomic analysis identified 8 proteins that were differentially serine-phosphorylated and 3 that were differentially tyrosine-phosphorylated after ATRA treatment. All proteins were significantly regulated (at least 0.5-fold down-regulated). Our results suggest that differentially phosphorylated proteins could be considered as more promising markers of differentiation for NB than differentially expressed proteins.

Citation: Mandili G, Marini C, Carta F, Zanini C, Prato M, et al. (2011) Identification of Phosphoproteins as Possible Differentiation Markers in All-Trans-Retinoic Acid-Treated Neuroblastoma Cells. PLoS ONE 6(5): e18254. doi:10.1371/journal.pone.0018254

Editor: Vladimir N. Uversky, University of South Florida College of Medicine, United States of America

Received: November 23, 2010; Accepted: February 24, 2011; Published: May 5, 2011

Copyright: © 2011 Mandili et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by the ‘Oncology Special Project’, Compagnia di San Paolo/FIRMS and by the ‘Ricerca sanitaria finalizzata’, Regione Piemonte (Italy). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors thank Dott. Franco Carta and Nurex S.R.L. for the free of charge mass spectrometry analyses. As Franco Carta is employed by Nurex S.R.L., Nurex did have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: Franco Carta is employed by Nurex S.R.L. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.

* E-mail: giuliana.giribaldi@unito.it

* These authors contributed equally to this work.

Introduction

Neuroblastic tumors account for 9–10% of pediatric tumors and neuroblastoma (NB) is the most frequent extra-cranial solid tumor and the first cause of death in pre-school age children [1]. NB is heterogenous in nature and mirrors the variety of cells that originate from the embryonic neural crest. These cells are capable of differentiating into an assortment of cells, including peripheral neurons and melanocytes [2,3,4,5,6]. NB is a tumor composed of undifferentiated or poorly differentiated neuroblasts. The arrested differentiation of neuroblasts is apparently an early event in the pathogenesis of NB [7]. According to the International Neuroblastoma Staging System, NB is classified into 4 stages: 1, 2A–B, 3 and 4, depending on the extent of spreading. Each stage is characterized by different overall survival [1]. Prognostic factors for NB are available and widely applied in pediatric oncology. Factors currently used for risk stratification are histology (according to the International Neuroblastoma Pathology Classification [INPC] and the mitosis karyorrhexis index), proto-oncogene MYCN amplification, deletion of the short arm of chromosome 1 and ploidy (cellular deoxyribonucleic acid [DNA] content) [8]. However, markers that identify areas of cellular differentiation/maturation on histological sections and with more sensitivity or precocity than morphology alone might provide additional factors and help to stratify patients according to risk groups. Like other tumors, NB can regress spontaneously and occurs at a higher frequency in NB than in any other type of cancer. HNK-1, Trk-A, H-Ras, GRP78, GRP73 and calreticulin, are biologic factors already identified that predicted a favorable outcome for NB patients associated with the differentiation or regression of NB cells at early clinical stages [9,10]. Spontaneous regression is most frequently observed in a particular subset of disseminated MYCN single-copy NB [non-amplified...
(NA), termed stage 4S (stage 4S-NA, S for special) [11]. This category includes patients up to one year of age, showing metastatic tumors at onset that infiltrate skin, liver and/or bone marrow, but not bone [1,12]. Stage 4S NB is one of the major puzzles for oncologists. Patients with disseminated tumors usually have very few chances to survive but stage 4S patients have an overall survival rate that approximates 75% at five years. In most of these cases, the tumor regresses spontaneously without any treatment or following supportive treatment only. Regression of this tumor is probably associated with differentiation and/or activation of programmed cell death [1]. Neuronal differentiation can be induced in neuronal precursor cells, including a wide number of NB cell lines, by exposure to all-trans-retinoic acid (ATRA), a retinoic acid isomorph compound commonly used for in vitro NB differentiation models [3,13,14]. Specifically, exposure of cells to physiological concentrations of ATRA: (i) increases the number of cells bearing neuritic processes and the length of these processes; (ii) generally inhibits cell proliferation. ATRA exerts its effects on gene transcription by binding to nuclear retinoic acid receptors (RARs) [5]. Although non-genomic actions of retinoids have been proposed, they have not been well investigated. In some cases, ATRA has been shown to rapidly activate protein kinases including extracellular-regulated kinase 1/2 [15,16,17,18,19], c-Jun N-terminal kinase [18,20], and phosphatidylinositol 3-kinase [18,21]. Protein kinase activation has been proposed to play a role in modulating neurite outgrowth [5] but protein substrates have not been comprehensively studied. In other cases retinoid has been shown to activate protein phosphatases, such as mitogen-activated protein kinase phosphatase 1 [22], protein phosphatase 2A and protein phosphatase 2B [23].

In this paper, we performed comparative proteomic and phosphoproteomic analysis using a 2-DE approach coupled with anti-phosphoserine and anti-phosphotyrosine western blotting. Our model was the human SJ-NK-P NB cell line, treated or not with ATRA for different times, to look for new potential differentiation markers.

Results

Effects of ATRA on NB cell morphology

SJ-N-KP cells were treated with 10 µM ATRA for 24 hours and 9 days. Figure 1 shows that after 24 hours few but consistent differences in cell morphology were already appreciable in treated cells, which started to elongate in comparison with control cells. After 9 days, ATRA-treated cells exhibited an extensive network of neurite process highlighting an evolution towards cell differentiation. Therefore ATRA induced differentiation in the SJ-N-KP NB cell line as expected.

Effect of ATRA on protein expression

In order to find new differentiation markers for NB, cell differentiation was mimicked by treatment with 10 µM ATRA. Comparative analysis of protein expression by 2-DE and mass spectrometry was then performed in SJ-N-KP cells treated or not for 24 hours or 9 days. Figure 2 shows representative 2-DE gel images of control cells (Figure 2A, 24 h and 2C, 9 days) and ATRA-treated cells (Fig. 2B, 24 h and 2D, 9 days) stained by comassic. Protein separation was very efficient, allowing the study of more than 500 protein spots. Tables 1 and 2 report the mass spectrometry identifications of all differentially expressed proteins. Seven proteins were differentially expressed (defined as at least 1.5-fold upregulated or 0.5-fold downregulated) in samples treated with ATRA for 24 hours (Table 1) and 5 proteins were differentially expressed in samples treated for 9 days (Table 2). However, the differential expression was statistically significant only for two proteins and only at the longest treatment time: nucleoside diphosphate kinase A (NDKA) (p<0.05) and reticulocalbin-1 (RCN1) (p<0.01), which were significantly downregulated after 9 days of ATRA treatment.

Effect of ATRA on protein phosphorylation

Since the phosphoproteome changes during cancer development and phosphoproteins may constitute useful markers for the early individuation of NB differentiation process, the effects of ATRA on serine- and tyrosine- phosphorylation patterns in NB cells were investigated. Firstly, we performed 1-DE analysis followed by western blotting with anti-phosphoserine and anti-phosphotyrosine antibodies in SJ-N-KP control cells and cells treated with 10 µM ATRA for 30 min, 60 min, 3 h, 9 h, 24 h, 48 h or 9 days. Figure 3 shows that even though serine- and tyrosine-phosphorylated proteins showed the same pattern in ATRA-treated and untreated cells, protein phosphorylation levels were significantly different in ATRA-treated cells at different times in comparison with control cells as shown by densitometric analysis of phosphoserine (panel A) and phosphotyrosine (panel B) western blotting. To better understand the effects of ATRA on protein phosphorylation, 2-DE analysis followed by western blotting with anti-phosphoserine and anti-phosphotyrosine antibodies was performed in cells treated or not with ATRA for

Figure 1. Phase contrast microscopy of NB cell line treated or not with ATRA. (A) SJ-N-KP control cells. (B) SJ-N-KP cells treated with 10 µM ATRA for 24 hours. (C) SJ-N-KP cells treated with 10 µM ATRA for 9 days. Magnification: 40×.

doi:10.1371/journal.pone.0018254.g001
30 min and 60 min. These two time periods were selected in order to identify the early changes induced by ATRA. Figure 4 shows the representative phosphorylation pattern in control cells (Fig. 4A and 4D), in cells treated with ATRA for 30 minutes (Fig. 4B and 4E) and in cells treated with ATRA for 60 minutes (Fig. 4C and 4F). Proteins found to be differentially phosphorylated and further identified are evidenced. In agreement with a greater rate of serine phosphorylation with respect to tyrosine phosphorylation, we observed more spots in anti-phosphoserine (upper panels) than in anti-phosphotyrosine (lower panels) western blots (even though more proteins were loaded for anti-phosphotyrosine western blots than for anti-phosphoserine blots). Table 3 reports the differentially phosphorylated proteins identified by mass spectrometry. We identified 1 protein that was differentially serine-phosphorylated after ATRA treatment at 30 minutes, and 7 proteins (from 8 spots) at 30 or 60 minutes. We also identified 1 protein (from 2 spots) that was differentially tyrosine phosphorylated at 30 and 60 minutes, and 2 proteins at 60 minutes. All differences were statistically significant (minimum cut-off: 0.5-fold down-regulation).

It is of note that after 30 and 60 minutes of ATRA treatment we did not observe any changes in protein expression (Fig. 4 panels G, H, I). The differentially phosphorylated proteins identified were classified into different groups depending on their cellular compartment localization and molecular function (Fig. 5 A and B).

**Discussion**

NB shows the highest rate of spontaneous regression of any human tumor, mainly due to differentiation and maturation of these highly malignant cells into neurons [24]. It is of interest to study the
molecular pathways driving spontaneous regression in NB to unravel the molecular basis of NB development, to look for new potential differentiation markers and to determine the differentiation therapies that can be used to treat patients. Proteome analysis is useful to identify differentially expressed proteins as possible new biomarkers, and the analysis of protein phosphorylation allows the study of the early events in the differentiation process, being thus an important goal in the identification of new early expressed biomarkers. Phosphorylation events in cellular signaling cascades triggered by a variety of cellular stimuli modulate protein function, leading to diverse cellular outcomes including cell division, growth, differentiation and death. Abnormal regulation of protein phosphorylation due to mutation or overexpression of signaling proteins could constitute biomarkers useful for cancer diagnostics and therapeutics [26]. It is well-known that the phosphotyrosine proteome in breast and liver cancer is indeed distinct [26]. In addition, Khadjavi et al. recently demonstrated that the protein tyrosine phosphorylation pattern is profoundly different in bladder cancer tissue biopsies in comparison with the surrounding healthy tissues and that phosphorylated proteins may represent a new valuable class of bladder cancer urinary markers (Khadjavi et al., in press). In this report, the phosphorylation status of ATRA-treated NB cells was studied using a 2-DE approach coupled with anti-phosphoserine and anti-phosphotyrosine western blotting and by mass spectrometry. Recent advances in mass spectrometry have clearly revolutionized the studies of phosphoprotein biochemistry, but gel electrophoresis-based proteomics remains one of the most appropriate methods for analyzing protein phosphorylation [27]. The present study identified several proteins with strikingly different expression or phosphorylation patterns in ATRA-treated NB cells with respect to control cells. However, more intense and evident changes in ATRA-treated cells were found in their protein expression or phosphorylation patterns in ATRA-treated NB cells.

Table 1. Proteins differentially expressed in neuroblastoma cell line following 24 h ATRA treatment as identified by MALDI-Tof MS.

| Spot number | Identified protein    | Accession number | MW (Da) | pI | Mascot Score | Matching Peptide/ Searched | Coverage (%) | Treated/Untreated Ratio ± SD |
|-------------|----------------------|------------------|---------|----|--------------|-----------------------------|--------------|------------------------------|
| 1           | Calreticulin precursor | P27797           | 48283   | 4.29 | 121          | 11/25                       | 27           | 3.1 ± 4.5                   |
| 2           | Vimentin             | P08670           | 53676   | 5.06 | 137          | 13/25                       | 36           | 2.2 ± 1.7                   |
| 3           | Vimentin             | P08670           | 53676   | 5.06 | 88           | 11/25                       | 24           | 21.2 ± 35.1                 |
| 4           | 78 kDa glucose-regulated protein precursor | P11021 | 72402   | 5.07 | 77           | 9/25                        | 19           | 1.9 ± 1.6                   |
| 5           | Ubiquitin-2          | Q9UD9H           | 65655   | 5.15 | 74           | 9/25                        | 17           | 4 ± 5.3                     |
| 6           | Protein disulfide-isomerase precursor | P07237 | 57480   | 4.76 | 127          | 12/25                       | 30           | 3.9 ± 1.8                   |
| 7           | ATP synthase subunit beta, mitochondrial precursor | P06576 | 56525   | 5.26 | 163          | 16/25                       | 32           | 2.4 ± 1.2                   |
| 8           | Glutathione S-transferase P | P09211 | 23569   | 5.43 | 56           | 5/25                        | 27           | 3.1 ± 2.1                   |

*Spot number were defined according to spot positions in 2-DE in Fig. 2.
**MW, molecular weight.
***p, isoelectric point.
†Number of matched mass values on number of total mass values searched.
‡The sequence coverage, which is calculated as the percentage of identified sequence to the complete sequence of the matched protein.
§Ratio between level of expression in treated and untreated cells. Standard deviation is indicated. For the significance two-sided Student’s t test was used (* p < 0.05, ** p < 0.01).

doi:10.1371/journal.pone.0018254.t001

Table 2. Proteins differentially expressed in neuroblastoma cell line following 9 days ATRA treatment as identified by MALDI-Tof MS.

| Spot number | Identified protein                                                                 | Accession number | MW (Da) | pI | Mascot Score | Matching Peptide/ Searched | Coverage (%) | Treated/Untreated Ratio ± SD |
|-------------|-----------------------------------------------------------------------------------|------------------|---------|----|--------------|-----------------------------|--------------|------------------------------|
| 9           | Reticulocalbin-1 precursor                                                        | Q15293           | 38866   | 4.86 | 61           | 6/25                        | 20           | 0.4 ± 0.1**                  |
| 10          | Nucleoside diphosphate kinase A                                                   | P15531           | 17309   | 5.83 | 76           | 6/25                        | 40           | 0.3 ± 0.3*                   |
| 11          | Vimentin                                                                          | P08670           | 53676   | 5.06 | 95           | 10/25                       | 26           | 3.9 ± 4.4                    |
| 12          | Nucleophosmin                                                                     | Q96EA5           | 32726   | 4.64 | 60           | 5/25                        | 25           | 3.9 ± 2.9                    |
| 13          | Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial precursor        | P33316           | 26975   | 9.65 | 80           | 6/25                        | 34           | 1.9 ± 1.8                    |

*Spot number were defined according to spot positions in 2-DE in Fig. 2.
**MW, molecular weight.
***p, isoelectric point.
†Number of matched mass values on number of total mass values searched.
‡The sequence coverage, which is calculated as the percentage of identified sequence to the complete sequence of the matched protein.
§Ratio between level of expression in treated and untreated cells. Standard deviation is indicated. For the significance two-sided Student’s t test was used (* p < 0.05, ** p < 0.01).

doi:10.1371/journal.pone.0018254.t002
Phosphoproteins as Differentiation Markers in NB

However, in many cases the biological meaning of these phosphorylative events needs to be elucidated.

In the present work, among the proteins with decreased phosphorylation levels at the beginning of differentiation program induced by ATRA, we found 3 mitochondrial proteins: stress-70 protein, ATP synthase and ATP-dependent Clp protease. It has been already demonstrated that the mitochondrial phosphoproteome comprises proteins belonging to different functional groups: metabolism, apoptosis, cell cycle, cell maintenance, transcription/translation, structural, chaperones and stress response [33]. As shown by Pagliarini et al., reversible phosphorylation is becoming an important means of regulating mitochondrial functions [34]. In this case, decreased stress-70 protein serine-phosphorylation levels can be related to the observed inhibition of human NB growth induced by ATRA [5,14], in agreement with evidence showing that, on the contrary, high phosphorylation levels at the beginning of differentiation program response [33]. As shown by Pagliarini et al., reversible phosphorylation of the ATP synthase β subunit has been elucidated, indicating that the phosphorylation event precedes the recruitment of mitochondrial 14-3-3 proteins with consequent inhibition of ATP synthase [36]. Some data are apparently in contrast with the present evidence showing a decrease of phosphorylation levels of the β subunit of the ATP synthase following ATRA treatment. For example, increased phosphorylation of mitochondrial ATP synthase beta-chain in apoptotic and terminally differentiated HL-60 cells has been demonstrated [37]. Of note, in the cited paper, ATRA treatment was prolonged for 120 hours. ATP-dependent Clp protease was already seen to be phosphorylated on serine in a leukemia cell line [38] but no data correlating protein phosphorylation and differentiation are currently available.

Among the differentially phosphorylated proteins identified here, a second group belonged to ER proteins: serine-
The phosphorylated protein disulfide-isomerase A6, serine-phosphorylated protein disulfide-isomerase A3 and tyrosine-phosphorylated 78 kDa glucose-regulated protein. As described below, all these proteins are involved in the ER stress response, which is notably induced by retinoic acid [39,40]. Protein disulfide-isomerase A6 phosphorylation on serine is well-documented [41,42,43,44] and there is evidence that this protein is serine-phosphorylated in G1 and M phases [44]; thus a decrease of phosphorylation of this protein fits well with data showing the inhibition of proliferation induced by ATRA [5,14]. Phosphorylation of disulfide-isomerase A3 is induced by a variety of stimuli such as leptin in the liver, angiotensin II in smooth muscle cells and gamma knife surgery in the brain; it is thought that the subcellular localization of protein disulfide-isomerase A3 is regulated by the phosphorylation of the tyrosine and serine residues [45]; however no data correlating protein phosphorylation and differentiation are available. Finally, it is well known that 78 kDa glucose-regulated protein can be tyrosine phosphorylated; it is a Src substrate [46] which must be tyrosine-phosphorylation for activation of PAK, a kinase important in mobility of malignant cells and proliferation [47]. Therefore the observed dephosphorylation of the 78 kDa glucose-regulated protein could be linked to data showing the inhibition of proliferation induced by ATRA [5,14]. Another category of proteins identified as differentially phosphorylated are the cytoskeleton proteins actin and vimentin. Both are known to be phosphorylated [48,49,50,51,52] in conjunction with cytoskeleton reorganization, which may conceivably occur during differentiation [53]. In particular, serine-phosphorylation of vimentin by Rho-associated kinase is involved in the agonist-induced neurite retraction of neuronal cells in NB [50]; these data are in accordance with our observation of a diminution of phosphorylation levels following differentiation in NB leading to neurite spreading. Moreover, the expression of vimentin also seems to be involved in NB differentiation induced by ATRA, but the data are not exhaustive [54,55]. Finally, eukaryotic
translational initiation factor 3, a cytoplasmic protein involved in the initiation of protein synthesis, was seen to be phosphorylated on tyrosine residues in fibroblast and lung cancer cell lines [56,57]; no data are available correlating its phosphorylation and differentiation.

Protein localisation is certainly important, but it also interesting to classify the described proteins according to their functions. Among the proteins identified as being differentially phosphorylated in present work, many are involved in folding mechanisms: stress-70 protein, ATP-dependent Clp protease, protein disulfide-isomerase A6, protein disulfide-isomerase A3, 78 kDa glucose-regulated protein. This is compatible with the reorganization of cellular status that occurs during differentiation with probable concomitant synthesis of new proteins. On the other hand, other proteins are glucose-related: protein disulfide-isomerase A3, 78 kDa glucose-regulated protein and stress-70 protein. 78 kDa glucose-regulated protein is essential for the differentiation of NB cells [9]. Moreover, it is known that 78 kDa glucose-regulated protein is also influenced by ATRA, but the effect appears to be strictly connected to cell origin, as ATRA downregulates 78 kDa glucose-regulated protein expression in foetal bovine chondrocytes [58] but upregulates its expression in hepatocarcinoma cells [59]. Stress-70 protein and protein disulfide-isomerase A3 have already been correlated with ATRA and differentiation, being overexpressed in NB cells following ATRA treatment [9,10].

### Table 3. Proteins differentially phosphorylated in neuroblastoma cell line following ATRA treatment as identified by MALDI-Tof MS.

| Spot number | Identified protein                              | Accession number | MW (Da) | Mascot Score | Matching Peptide | Coverage (%) | p-Ser 30: Treated/Untreated Ratio ± SD | p-Ser 60: Treated/Untreated Ratio ± SD | p-Tyr 30: Treated/Untreated Ratio ± SD | p-Tyr 60: Treated/Untreated Ratio ± SD |
|-------------|------------------------------------------------|------------------|---------|--------------|------------------|-------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|
| 1           | Stress-70 protein, mitochondrial precursor     | P38646           | 73920   | 5.87 85      | 11/25            | 15          | 0.3±0.3**                           | 0.5±0.4                              |                                      |                                      |
| 2           | ATP-dependent Clp protease ATP-binding subunit ClpX-like, mitochondrial precursor | O76031           | 69922   | 7.51 57      | 6/25             | 14          | 0.6±0.9                             | 0.4±0.3*                             |                                      |                                      |
| 3           | Actin, cytoplasmic 1                          | P60709           | 42052   | 5.29 124     | 11/25            | 36          | 0.5±0.4                             | 0.4±0.2*                             |                                      |                                      |
| 4           | Actin, cytoplasmic 1                          | P63261           | 42108   | 5.31 124     | 11/25            | 36          |                                      |                                      |                                      |                                      |
| 5           | Actin, cytoplasmic 1                          | P60709           | 42052   | 5.29 96      | 8/25             | 26          | 0.2±0.4*                            |                                      |                                      |                                      |
| 6           | Actin, cytoplasmic 1                          | P63261           | 42108   | 5.31 96      | 8/25             | 26          |                                      |                                      |                                      |                                      |
| 7           | ATP synthase subunit beta, mitochondrial precursor | P06576           | 56525   | 5.26 159     | 15/25            | 41          | 0.3±0.3*                            | 0.4±0.8                              |                                      |                                      |
| 8           | Vimentin                                      | P08670           | 53676   | 5.06 253     | 20/25            | 54          | 0.3±0.4                             | 0.5±0.5*                             |                                      |                                      |
| 9           | Vimentin                                      | P08670           | 53676   | 5.06 58      | 7/25             | 22          | 0.1±0.2                            | 0.2±0.4*                             |                                      |                                      |
| 10          | Protein disulfide-isomerase A6 precursor       | Q15084           | 48490   | 4.95 58      | 6/25             | 26          |                                      |                                      |                                      |                                      |
| 11          | 78 kDa glucose-regulated protein precursor    | P11021           | 72402   | 5.07 174     | 16/25            | 28          | 0.1±0.2**                           | 1±1.4                                |                                      |                                      |
| 12          | 78 kDa glucose-regulated protein precursor    | P11021           | 72402   | 5.07 189     | 17/25            | 30          | 0.3±0.5**                           | 0.1±0.1**                            |                                      |                                      |
| 13          | Eukaryotic translation initiation factor 3 subunit 2 | Q13347           | 36878   | 5.38 157     | 13/25            | 45          | 0.2±0.2**                            |                                      |                                      |                                      |

*Spot number were defined according to spot positions in 2-DE in Fig. 4.

*Molecular weight.

*pI, isoelectric point.

*Number of matched mass values on number of total mass values searched.

*The sequence coverage, which is calculated as the percentage of identified sequence to the complete sequence of the matched protein.

*Ratio between level of phosphorylation in treated and untreated cells. Standard deviation is indicated. For the significance two-sided Student’s t test was used (* p<0.05, ** p<0.01).

doi:10.1371/journal.pone.0018254.t003
In conclusion, protein phosphorylation status in NB cells could be an interesting potential biomarker of early differentiation. A future analysis of the phosphorylation status of proteins in NB tissues utilizing specific phosphorylated-protein antibodies could permit the validation of these proteins as candidates for application in the clinical practice. The use of markers of maturation could be very important to detect the onset of differentiation and to choose the most appropriate clinical treatment. Additionally, there is increasing interest in the application of differentiation inducers in the treatment of NB, possibly in order to mimic the differentiation process that occurs in stadium 4S-tumours, which can regress spontaneously [7]. Thus, a more exhaustive comprehension of the phenomena described in the present study can also help to better understand the differentiation mechanisms in forms of NB that do not regress spontaneously.

**Materials and Methods**

**Chemicals and reagents**

RPMI 1640, streptomycin, penicillin, ATRA, protease and phosphatase inhibitors, ammonium persulfate (APS), bromophenol blue, glycerol, N,N,N',N'-tetramethylethylene-diamine (TEMED), sodium dodecyl sulfate (SDS), TRIZMA, urea, 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulphonate (CHAPS), dithiothreitol (DTT), iodoacetamide were purchased from Sigma-Aldrich (St. Louis, MO, USA). DC Protein assay kit, acrylamide, agarose, ready-made immobilized pH gradient (IPG) strip (7- and 17-cm IPG strips, pH 4–7), enhanced chemiluminescence kit were purchased from Bio-Rad (Hercules, CA, USA). Ampholine pH 3.5–10 and 5–8 were obtained from GE Healthcare (MI, ITALY). Fetal bovine serum USA Origin was purchased from EuroClone (Paignton, UK). PVDF membrane...
Immobilon-P was obtained from Millipore (MI, Italy). Antibodies anti-phosphoserine PSR-45, anti-phosphotyrosine PY-20 and anti-goat IgG horseradish-peroxidase-labeled were purchased from Sigma, anti-phosphotyrosine PY99 and anti-actin from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and anti-mouse IgG horseradish-peroxidases e-labeled from GE Healthcare Bio-Sciences.

Cell culture and ATRA treatment
Established NB human cell line SJ-N-KP [60] was cultured at 37°C, 5% CO₂ in RPMI 1640 supplemented with 10% heat inactivated foetal bovine serum USA Origin, 100 µg/mL streptomycin and 100 U/mL penicillin. Cells were cultured in gel on the Mini Protean system (Bio-Rad).

Mono-dimensional electrophoresis (1-DE)
After adding of Laemmli buffer [63], samples were boiled for 5 min and 60 mM final concentration DTT, was added. 15 µg of each protein sample were analysed on 10% SDS-polyacrylamide gels on the Mini Protean system (Bio-Rad). For large format second dimension, 8×7×0.1 cm 10% acrylamide gels were run on the Mini Protean system (Bio-Rad). For large format second dimension, 10×20×0.1 cm 10% acrylamide gels were run on the Bio-Rad XI cell. Electrophoresis was performed for 30 min at 50 V and then was continued at 100 V until the Bromophenol blue front reached the lower limit of the gel. Analytical gels were stained with silver staining as described [64] and preparative gels with colloidal Coomassie (18% v/v ethanol, 15% w/v ammonium sulfate, 2% v/v phosphoric acid, 0.2% w/v Coomassie G-250) for 4 h and destained with water.

Western blotting
Small format gels were transferred to a PVDF membrane. Membranes were blocked with 3% w/v BSA in PBST (PBS supplemented with polyoxyethylene sorbitan monolaureate [Tween 20] 0.1% v/v) for 1 h and then membranes were washed three times with PBST and probed with a 1:400 dilution of anti-phosphoproteins PSR-45 or 1:400 dilution of two mixed 1:1 anti-phosphotyrosines PSR-45 or 1:400 dilution of two mixed 1:1 anti-phosphotyrosine (PY20 and PY99) O.N. at 4°C. Membranes were washed six times with PBST; incubated for 1 hour with a 1:10000 dilution of anti-mouse IgG horseradish-peroxidase-labeled antibody and immunoreactivity was detected with an enhanced chemiluminescence kit. Afterwards membranes with 1-DE analysis were stripped (2 hours washing with glycine 20 mM pH 2.2, Tween 1% v/v, SDS 0.1% w/v) and probed with 1:100 dilution of anti-actin antibodies for normalization of the data.

Protein identification by mass spectrometry and database search
Coomassie G-stained spots were excised from 2-DE preparative gels; destaining and in-gel enzymatic digestion were performed as previously described [63]. Briefly each spot was destained with 100 µl of 50% v/v acetonitrile in 5 mM ammonium bicarbonate and dried with 100 µl of acetonitrile. Each dried gel piece was rehydrated for 40 min at 4°C in 10 µl of a digestion buffer containing 5 mM ammonium bicarbonate, and 10 ng/µl of trypsin. Digestion was allowed to proceed overnight at 37°C and the peptides mixtures were stored at 4°C until assayed. All digests were analyzed by MALDI-TOF (ToI Spec SE, MicroMass) equipped with a delayed extraction unit. Peptides solution was prepared with equal volumes of saturated 2-cyano-4-hydroxycynamic acid solution in 40% v/v acetonitrile-0.1% v/v trifluoroacetic acid. The MALDI-TOF was calibrated with a mix of PEG (PEG 1000, 2000 and 3000 with the ratio 1:1:2) and mass spectra were acquired in the positive-ion mode. Peak lists were generated with ProteinLynx Data Preparation (ProteinLynx Global Server 2.2.5) using the following parameters: external calibration with lock mass using mass 2465.1989 Da of ACTH, background subtract type adaptive combining all scans, performing deisotoping with a threshold of 1%. The 25 most intense masses were used for database searches against the SWISSPROT database (release 2011-01 of 11-Jan-11) using the search free program MASCOT 2.3.02 (http://www.matrixscience.com). The following parame-
ters were used in the searches: taxa Homo sapiens, trypsin digest, one missed cleavage by trypsin, carbamidomethylation of cysteine as fixed modification, methionine oxidation and serine or tyrosine phosphorylation (only for differential phosphoproteomic analysis) as variable modifications and maximum error allowed 100 ppm. Were taken on to consideration only protein with a Mascot score >35.

Statistical analysis
Data from densitometric analysis were used as values of proteins phosphorylation in 1-DE experiments. Data from image analysis were used as values of protein expression or phosphorylation in 2-DE experiments. To verify the significance of the expression and phosphorylation of proteins in ATRA treated cells vs control cells, two-sided Student’s t test was used. Experiments were performed in triplicate. Statistical significance was set at p-values<0.05. In 2-DE experiments proteins were classified as differentially expressed or phosphorylated if ratio in spot intensity between treated cells and control cells was greater than 1.5-fold (protein overexpressed or overphosphorylated) or lower than 0.5-fold (protein underexpressed or underphosphorylated).

Author Contributions
Conceived and designed the experiments: GM CZ FT. Performed the experiments: GM CM FC AK. Analyzed the data: GM AK FT GG MP. Contributed reagents/materials/analysis tools: FC. Wrote the paper: GM MP GG.

References
1. Tonini G, Pistoia V (2006) Molecularly guided therapy of neuroblastoma: a review of different approaches. Curr Pharm Des 12: 2303–2317.
2. Abemayor E, Sidell N (1989) Human neuroblastoma cell lines as models for the in vitro study of neoplastic and neuronal cell differentiation. Environ Health Perspect 80: 3–15.
3. Ciccarone V, Spengler B, Meyers M, Biedler J, Ross R (1989) Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages. Cancer Res 49: 219–225.
4. Thiele C (1991) Biology of pediatric peripheral neuroectodermal tumors. Cancer Metastasis Rev. 10: 311–319.
5. Clagett-Dame M, McNeill E, Muley P (2006) Role of all-trans retinoic acid in neurite outgrowth and axonal elongation. J Neurobiol 66: 739–756.
6. Zanini C, Giribaldi G, Mandili G, Carta F, Crescenzi N, et al. (2007) Inhibition of heat shock proteins (HSP) expression by quercetin and differential doxorubicin sensitization in neuroblastoma and Ewing’s sarcoma cell lines. J Neurochem 103: 1344–1354.
7. Voigt A, Zintel F (2003) Effects of retinoic acid on proliferation, apoptotic cytotoxicity, migration, and invasion of neuroblastoma cells. Med Pediatr Oncol 40: 205–213.
8. Schob K, Shimada H, Yoshii V, Brodeur GM (2000) Neuroblastic tumours of adrenal gland and sympathetic nervous system. In: IARC, editor. Pathology and genetics of tumours of the nervous system. Lyon: IARC.
9. Hsu W, Hsieh C, Kung Y, Kuo M, Tsao P, et al. (2005) GRP78 expression correlates with histologic differentiation and favorable prognosis in neuroblastoma. Int J Cancer 113: 920–927.
10. Hsu W, Lee H, Juan H, Wang Y, Wang B, et al. (2006) Identification of GRP75 as an independent favorable prognostic marker of neuroblastoma by a proteomics analysis. Clin Cancer Res 12: 6237–6245.
11. Westernmann F, Fassnacht D, Brander A, Baeuerle P, Heinrich K, et al. (2008) Distinct transcriptional MYC/NEU /MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol 9: R150.
12. Brodeur G, Pritchard J, Berthold F, Carlsen N, Castel V, et al. (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11: 1466–1477.
13. Sidell N, Altman A, Haussler M, Seeger R (1983) Effects of retinoic acid (RA) on the growth and phenotypic expression of several human neuroblastoma cell lines. Exp Cell Res 148: 21–30.
14. Molino G, Thiele C, Knight R, Piacentini M (1997) Retinoids and the control of cell diversification in human neuroblastoma cells. Perspect 80: 3–15.
15. Sanli U, Uslu K, Karahalil B, Sezgin C, Schi N, et al. (2003) Alterations in the activity and expression of serine/threonine protein phosphatases during all trans retinoic acid-induced apoptosis in breast cancer cells. Oncol Rep 10: 2003–2008.
16. Cimmino F, Spano D, Capasso M, Zambrano N, Russo R, et al. (2007) Comparative proteomic expression profile in all-trans retinoic acid differentiated neuroblastoma cell line. J Proteome Res 6: 2350–2364.
17. Kim J, Tannerbaum S, White F (2005) Global phosphoproteome of HT-29 human colon adenocarcinoma cells. J Proteome Res 4: 1339–1346.
18. Lin Y (2005) Mining the tumor phosphoproteome for cancer markers. Clin Cancer Res 11: 3163–3169.
19. Salih E (2005) Phosphoproteomics by mass spectrometry and classical protein chemistry approaches. Mass Spectrom Rev 24: 829–846.
20. Zanini C, Pulera F, Carta F, Giribaldi G, Mandili G, et al. (2008) Proteomic identification of heat shock protein 27 as a differentiation and prognostic marker in neuroblastoma but not in Ewing’s sarcoma. Virochows Arch 352: 157–167.
21. Pettig W, Spengler B, Chessa P, Old L, Biedler J (1987) Coordinate changes in neuronal phenotype and surface antigen expression in human neuroblastoma cell variants. Cancer Res 47: 1383–1389.
22. Hunter T (1991) Protein kinase classification. Methods Enzymol 200: 3–37.
23. Becker G, Ploski J, Ploski R, Zaborska M, Turczyn M, et al. (2007) Large-scale proteome analysis of human umbilical vein endothelial cell differentiation. J Proteome Res 6: 669–676.
24. Pagliarini D, Dixon J (2006) Mitochondrial modulation: reversible phosphorylation takes center stage? Trends Biochem Sci 31: 26–34.
25. Kanaai M, Ma Z, Irumi H, Kim S, Mattison C, et al. (2007) Physical and functional interaction between mortalin and Mpi1 protein. Genes Cells 12: 797–810.
26. Bunney T, van Walraven H, de Boer A (2001) 14–3–3 protein is a regulator of the mitochondrial and chloroplast ATP synthase. Proc Natl Acad Sci U S A 98: 4249–4254.
27. Navakauskaite R, Treigte G, Gineitien A, Magnusson K (2004) Identification of apoptotic tyrosine-phosphorylated proteins after etoposide or retinoic acid treatment. Proteomics 4: 1029–1041.
28. Mayya V, Lundgren D, Hwang S, Rezaul K, Wu L, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2: ra46.
29. Latasa M, Iruero M, Moran-Gonzalez A, Aranda A, Cosgaya J (2010) Retinoic acid regulates myelin formation in the peripheral nervous system. Glia 58: 1451–1464.
30. Xu Y, Guan D, Yang M, Wang H, Shen Z (2010) All-trans-retinoic acid mediates endoplasmic reticulum stress in N-acetylcysteinamidraniflavone V repressed human hepatocarcinoma cells by perturbing homeostatic metabolism. J Cell Biochem 109: 486–477.
31. Beaudesert S, Jedlychowski M, Schwartz D, Elias J, Villen J, et al. (2004) Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci U S A 101: 12130–12135.
32. Beaudesert S, Villen J, Gerber S, Rush J, Giggi S (2006) A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat Biotechnol 24: 1265–1292.
43. Olsen J, Blagoev B, Gnad F, Macek B, Kumar C, et al. (2006) Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 127: 635–648.

44. Dephoure N, Zhou C, Villén J, Beausselin S, Bakalarski C, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105: 10762–10767.

45. Akazawa Y, Saito Y, Nishio K, Horie M, Kinumi T, et al. (2010) Proteomic characterization of the striatum and midbrain treated with 6-hydroxydopamine: alteration of 58-kDa glucose-regulated protein and C/EBP homologous protein. Free Radic. Res 44: 410–421.

46. Carlino A, Toledo H, Vidal V, Redfield B, Strassman J, et al. (1994) BiP is a substrate for src kinase in vitro. Biochem Biophys Res Commun 201: 1148–1153.

47. Misra U, Deedwania R, Pizzo S (2005) Binding of activated alpha2-macroglobulin to its cell surface receptor GRP78 in 1-LN prostate cancer cells regulates PAK-2-dependent activation of LIMK. J Biol Chem 280: 26278–26286.

48. Ohta Y, Akiyama T, Nishida E, Sakai H (1987) Protein kinase C and cAMP-dependent protein kinase induce opposite effects on actin polymerizability. FEBS Lett 222: 305–310.

49. Reiss N, Oplatka A, Hermon J, Naor Z (1996) Phosphatidylserine directs differential phosphorylation of actin and glyceraldehyde-3-phosphate dehydrogenase by protein kinase C: possible implications for regulation of actin polymerizability. FEBS Lett 222: 305–310.

50. Nakamura Y, Hashimoto R, Amazo M, Nagata K, Matsumoto N, et al. (2000) Localized phosphorylation of vimentin by rho-kinase in neuroblastoma N2a cells. Genes Cells 5: 823–837.

51. Gu L, Zhang H, Chen Q, Chen J (2003) Calyculin A-induced actin phosphorylation and depolymerization in renal epithelial cells. Cell Motil Cytoskeleton 54: 236–295.

52. Tanaka T, Akatsu S, Ozeki M, Shirase T, Hiai H, et al. (2004) Redox regulation of annexin 2 and its implications for oxidative stress-induced renal carcinogenesis and metastasis. Oncogene 23: 3980–3989.

53. Inberg A, Bogoch Y, Bledi Y, Zitterbart K, Hermanova M, Sterba J, et al. (2010) Enhancement of ATRA-induced differentiation of neuroblastoma cells with LON/COX inhibitors: an expression profiling study. J Exp Clin Cancer Res 29: 45.

54. Amendola R, Martinez R, Negroni A, Venturelli D, Tanno B, et al. (2001) DR-nm23 expression affects neuroblastoma cell differentiation, integrin expression, and adhesion characteristics. Med Pediatr Oncol 36: 93–96.

55. Ueda K (2001) Detection of the retinoic acid-regulated genes in a RTBM1 neuroblastoma cell line using cDNA microarray. Hum Gene Med J 48: 159–164.

56. Rush J, Moritz A, Lee K, Guo A, Goss V, et al. (2005) Immunofluorescence profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol 23: 94–101.

57. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, et al. (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131: 1190–1203.

58. Freyria A, Ronzière M, Bouillon M, Herbage D (1995) Effect of retinoic acid on protein synthesis by foetal bovine chondrocytes in high-density culture: down-regulation of the glucose-regulated protein, GRP-78, and type II collagen. Biochem J 303(Pt 2): 391–396.

59. Xu Y, Lu Y, Fan K, Shen Z (2007) Apoptosis induced by all-trans retinoic acid in N-acetylg glucosaminyltransferase V repressed human hepatocarcinoma cells is mediated through endoplasmic reticulum stress. J Cell Biochem 100: 773–782.

60. Izardto G, Deaglio S, Cocito D, Migliaretti G, Fervero E, et al. (2005) Immunodetection of anti-MAG IgM antibody by cross-reactivity to LAN-1 neuroblastoma cells. J Neuroimmunol 161: 78–86.

61. Chlapek P, Redova M, Zitterbart K, Hermanova M, Sierba J, et al. (2010) Immunodetection of anti-MAG IgM antibody by cross-reactivity to LAN-1 neuroblastoma cells. J Neuroimmunol 161: 78–86.

62. Futami H, Sakai R (2010) All-trans retinoic acid downregulates ALK in neuroblastoma cell lines and induces apoptosis in neuroblastoma cell lines with activated ALK. Cancer Lett 297: 220–225.

63. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680–685.

64. Oakley B, Kirsch D, Morris N (1980) A simplified ultraviolet silver stain for detecting proteins in polyacrylamide gels. Anal Biochem 105: 363–365.

65. Barbero G, Carta F, Giribaldi G, Mandili G, Crobu S, et al. (2006) Protein/RNA coextraction and small two-dimensional polyacrylamide gel electrophoresis for proteomic/gene expression analysis of renal cancer biopsies. Anal Biochem 349: 62–71.